12,163 BioNTech SE Sponsored ADR $BNTX Shares Sold by Crocodile Capital Partners GmbH

Crocodile Capital Partners GmbH lowered its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 41.1% during the third quarter, HoldingsChannel.com reports. The fund owned 17,423 shares of the company’s stock after selling 12,163 shares during the period. BioNTech accounts for 1.1% of Crocodile Capital Partners GmbH’s portfolio, making the stock its 7th largest holding. Crocodile Capital Partners GmbH’s holdings in BioNTech were worth $1,713,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Flossbach Von Storch SE acquired a new stake in BioNTech during the second quarter valued at approximately $207,142,000. First Trust Advisors LP raised its stake in BioNTech by 116.0% during the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after acquiring an additional 451,124 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in BioNTech during the second quarter worth $39,385,000. SEB Asset Management AB bought a new position in shares of BioNTech during the first quarter valued at $17,804,000. Finally, Bank of America Corp DE lifted its holdings in shares of BioNTech by 22.6% during the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after acquiring an additional 166,432 shares during the period. Institutional investors own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on BNTX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a report on Friday, October 2nd. Berenberg Bank set a $140.00 price target on shares of BioNTech in a research report on Wednesday, September 16th. Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. BMO Capital Markets lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $128.00 to $105.00 in a report on Tuesday, September 8th. Finally, Morgan Stanley dropped their price objective on shares of BioNTech from $115.00 to $114.00 and set an “overweight” rating for the company in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and an average target price of $125.69.

Insider Activity at BioNTech

In related news, CEO Ugur Sahin sold 24,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 7th. The shares were sold at an average price of $95.86, for a total value of $2,300,640.00. Following the completion of the sale, the chief executive officer owned 63,209 shares of the company’s stock, valued at $6,059,214.74. This trade represents a 27.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 744,000 shares of company stock worth $73,301,215 over the last quarter. 19.20% of the stock is owned by corporate insiders.

BioNTech Price Performance

Shares of BNTX stock opened at $92.06 on Friday. The stock’s fifty day moving average is $99.04 and its 200-day moving average is $95.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The stock has a market capitalization of $23.28 billion, a PE ratio of -11.76 and a beta of 1.25. BioNTech SE Sponsored ADR has a 52 week low of $79.52 and a 52 week high of $124.00.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The business had revenue of $122.31 million during the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business’s quarterly revenue was down 59.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.60) earnings per share. Equities research analysts expect that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.